We are live on ! Find out more
PASG icon

Passage Bio
PASG

32 hedge funds and large institutions have $13.2M invested in Passage Bio in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

49.05% more ownership

Funds ownership: 2.82% → 51.87% (+49%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

18% less funds holding

Funds holding: 39 → 32 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

60% less capital invested

Capital invested by funds: $33M → $13.2M (-$19.8M)

Holders
32
Holders Change
-7
Holders Change %
-17.95%
% of All Funds
0.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
13
Reduced
6
Closed
15
Calls
$18K
Puts
–
Net Calls
+$18K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$1.12M
2
Renaissance Technologies
Renaissance Technologies
New York
+$209K
3
Squarepoint
Squarepoint
New York
+$164K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$104K
5
Citadel Advisors
Citadel Advisors
Florida
+$46.7K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$1.7M
2
NLVP
New Leaf Venture Partners
New York
-$261K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$147K
4
State Street
State Street
Massachusetts
-$62.8K
5
RC
RBF Capital
California
-$57.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$5.01M +$1.12M +160,856 +35%
VPC
2
Vestal Point Capital
New York
$2.45M – – –
EAM
3
Erste Asset Management
Austria
$999K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$937K +$104K +15,002 +15%
Renaissance Technologies
5
Renaissance Technologies
New York
$809K +$209K +29,969 +42%
NLVP
6
New Leaf Venture Partners
New York
$702K -$261K -37,470 -30%
TCM
7
Tang Capital Management
California
$602K – – –
O
8
OrbiMed
New York
$474K -$1.7M -243,719 -80%
BlackRock
9
BlackRock
New York
$239K +$42 +6 +0%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$219K +$2.46K +354 +1%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$204K -$147K -21,120 -45%
Squarepoint
12
Squarepoint
New York
$188K +$164K +23,500 New
BCM
13
Bridgeway Capital Management
Texas
$167K +$7 +1 +0%
Citadel Advisors
14
Citadel Advisors
Florida
$153K +$46.7K +6,707 +54%
FT
15
Fiduciary Trust
Massachusetts
$86.3K – – –
Morgan Stanley
16
Morgan Stanley
New York
$2.71K +$84 +12 +4%
TRCT
17
Tower Research Capital (TRC)
New York
$2.32K -$8.18K -1,175 -80%
Barclays
18
Barclays
United Kingdom
$1.7K +$7 +1 +0.5%
MCM
19
MAI Capital Management
Ohio
$1.61K +$1.39K +200 New
SS
20
SBI Securities
Japan
$1.14K -$21 -3 -2%
Citigroup
21
Citigroup
New York
$617 +$536 +77 New
Bank of America
22
Bank of America
North Carolina
$225 +$21 +3 +12%
Osaic Holdings
23
Osaic Holdings
Arizona
$141 -$557 -80 -80%
UBS Group
24
UBS Group
Switzerland
$137 +$118 +17 New
PA
25
Parallel Advisors
California
$128 +$111 +16 New
1
2

PASG Hedge Fund Activity: Q3 2025 in Review

32 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2025, worth a combined $13.2M — down 60% from $33M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PASG and 8 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 13 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $1.12M. The largest seller was OrbiMed, cutting an estimated $1.7M.

  • 32 institutional investors held Passage Bio (PASG) as of Q3 2025, down from 39 in Q2 2025.
  • Funds reported $13.2M of Passage Bio stock for Q3 2025, down 60% quarter-over-quarter.
  • 8 funds opened new Passage Bio positions in Q3 2025 and 15 closed out, a net change of -7 holders.
  • The largest Passage Bio buyer in Q3 2025 was Lynx1 Capital Management, an estimated $1.12M added.
  • The largest Passage Bio seller in Q3 2025 was OrbiMed, an estimated $1.7M sold.

Based on aggregated 13F filings for Q3 2025.